Transgene Engages with Key Biotech Industry Platforms

Transgene, a biotech firm specializing in virus-based cancer immunotherapies, is set to engage with significant industry gatherings throughout June and July 2025. The company will participate in the BIO International Convention in Boston, the Mid&Small Caps Conference in Paris, the International Neoantigen Summit in Amsterdam, and the International Academy of Oral Oncology in Liverpool. These meetings provide Transgene an opportunity to discuss the promising clinical data of its personalized neoantigen cancer vaccine, TG4050, presented recently at the ASCO Annual Meeting.

Collaborating with Professor Christian Ottensmeier, Transgene has addressed the current treatment needs and landscape for head and neck cancer patients. These discussions highlight the significance of TG4050 in advancing personalized cancer treatment. The company continues to push the boundaries with its myvac® platform and other viral vector-based immunotherapies.